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Aim: To describe the safety and efficacy of HFOV as a rescue therapy for lung haemorrhage.
Methods: We conducted a retrospective case study of nine children. Lung haemorrhage was
defined as large amounts of blood-stained effluent not attributable to a cardiovascular malfor-
mation or trauma, with bilateral opacities on chest X-ray. HFOV was started when conventional
ventilation was ineffective in controlling the haemorrhage resulting in hypoxaemia or
hypercarbia. A strategy was used aiming at tamponading transudation of oedema and
decreasing blood flow from ruptured vessels.
Results: Seven infants improved significantly on HFOV. Two infants died, both showing an
increasing oxygenation index.
Conclusions: HFOV therapy can be life-saving in massive lung haemorrhage in children, using
a strategy with high pressures to tamponade transudation of haemorrhagic oedema, and to
decrease blood flow from ruptured arterioles by reducing blood flow and increasing intratho-
racic pressure. Similar to previous trials, an increasing oxygenation index was a sign of
imminent death.
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HFOV in severe lung haemorrhage 93Introduction from the endotracheal tube. General supportive careHaemorrhagic pulmonary oedema (HPO) is a relatively
uncommon but potentially life threatening event in chil-
dren. In general it is a presenting symptom of an underlying
condition, often with heterogeneous causes beyond the
neonatal period. In most instances pulmonary haemorrhage
is a reflection of advanced pulmonary oedema, although
true traumatic haemorrhage can occur as well.1,2 Accu-
mulation of the haemorrhagic fluid in the alveoli will result
in both airway obstruction and ventilationeperfusion
mismatch with acute gas exchange failure. These gas
exchange disturbances are often refractory to conventional
mechanical ventilation (CMV) even with high peak and end-
expiratory pressures with consequently a substantial
mortality and morbidity due to barotrauma or volutrauma.1
Although mortality is high (up to 50%), HPO does not
significantly increase the risk of later pulmonary or neuro-
developmental disabilities among those who survive,
justifying the use of invasive and aggressive therapies such
as extracorporeal membrane oxygenation (ECMO).3,4
Although high-frequency oscillatory ventilation (HFOV) has
previously been shown to be effective in severe respiratory
failure, data on the use of HFOV for HPO in childhood are
scant.5e8 We report our experience with HFOV in nine
patients with lung haemorrhage who deteriorated on CMV.
Methods
A retrospective case study was performed to identify all
children who developed HPO at the University Medical
Centre, Utrecht, the VU University Medical Centre,
Amsterdam, the Netherlands, and Queen Paola Children’s
Hospital, Antwerp, Belgium. All three facilities are regional
referral centres for paediatric intensive care, caring for
approximately 700e1000 new paediatric intensive care
patients annually. Acute pulmonary haemorrhage was
defined as the presence of a large amount of blood-stained
lung effluent which could not be attributed to a cardiac or
vascular malformation or known extrinsic trauma, with
bilateral opacities on chest X-ray.
All patients were initially ventilated with either pressure
regulated volume controlled or biphasic positive airway
pressure (BiPAP) controlled ventilation (Servo 300, Siemens,
or Evita 2 Dura, Dra¨ger). To control pulmonary haemor-
rhage, mean airway pressure (Paw) was increased and
patients were put in prone position to improve oxygenation.
All patients had indwelling catheters for pressure moni-
toring, analysis of arterial blood gases and infusion of
medication and fluids. HFOV (SensorMedics 3100A, Yorba
Linda, CA) was started when CMV was not effective in
controlling the pulmonary haemorrhage, resulting in
ongoing efflux of blood-stained fluid with progressive
hypoxaemia, hypercarbia and/or severe atelectasis. The
‘‘open-lung strategy’’ was employed during HFOV, with high
continuous distending pressure (CDP), designed primarily to
rapidly recruit and maintain lung volume in diffuse alveolar
disease.5,6 The haemorrhage was deemed under control
when arterial oxygen saturation (SaO2) was above 90% with
an FiO2 of less than 0.6, arterial pH was above 7.25 irre-
spective of PaCO2 and there was no longer blood obtainedremained unchanged during transition. In children less than
10 kg, we started with a frequency of 10e15 Hz and above
10 kg, 8 Hz. Whenever respiratory acidosis persisted,
frequency was decreased. Proximal pressure amplitude was
adjusted according to chest wall vibrations and PaCO2.
Inspiratory timewas set at33%.Biasgasflowwas20e 40 l/min
as necessary to maintain CDP. We use inline suction
catheters. Suctioning usually is not necessary for the first
24 h after transition to HFOV. If needed, CDP is routinely
set 2e3 cm higher during suctioning with return to base-
line values within 20 min afterwards.
We started with an FiO2 of 1.0 and CDP 4 cm above Paw
during CMV. Subsequently CDP was increased rapidly with
steps of 2e3 cmH2O, until pulmonary haemorrhage was
macroscopically controlled with visual cessation of
bleeding, and oxygenation targets were reached. The
Institutional Review Board of our hospital approved the
report of these cases. A waiver of informed consent was
granted for retrospective data analysis.
Statistics
Values are reported as median and quartiles (Q1eQ3). They
were compared to baseline values on CMV, using Wilcoxon’s
signed ranks test (SPSS 11.5 for Windows, SPSS Software,
Chicago, IL, USA). Statistical significance was assumed
when p-value was less than 0.05.
Results
Conventional mechanical ventilation
Table 1 shows patient characteristics and CMV values prior
to translation. In five children HPO presented within 24 h
after initiation of CMV. Three children suffered from
pneumonia, three showed massive bleeding after thoracic
surgery and two showed idiopathic pulmonary haemor-
rhage. One child, a 4-week-old Down patient, with atrio-
ventricular septum defect and severe tracheomalacia, had
been on CMV for more than 3 weeks, requiring high venti-
latory support due to sepsis and severe recurrent atelec-
tasis of the lung. On day 22 she developed HPO, probably
due to barotrauma.
Most of the children were on CMV for a very short period
with a median period (Q1eQ3) of 1 (0.6e6). Just before
transition to HFOV, seven of the children showed progres-
sive hypoxemia (Oxygenation Index (OI) >13), five of them
in combination with respiratory acidosis (pH <7.25, modi-
fied ventilatory index (MVI) >40). Two had ongoing visual
bleeding with atelectasis. All except two (patients 4 and 6)
showed a normal coagulation status.
High-frequency oscillatory ventilation
Nine children were treated with HFOV for HPO. Median
duration (Q1eQ3) on HFOV was 9 days (3e15). Median
maximum CDP was 28 cmH2O (22e41). HFOV improved
oxygenation in seven of nine infants. Figure 1 shows the OI
on CMV and during the first 72 h on HFOV of all responders.
Compared to baseline values there is a significant decrease
Table 1 Patient characteristics with CMV characteristics prior to translation.
Patient Sex Weight Age History Diagnosis PIP PEEP pH PaCO2 MVI PaO2/FiO2 OI
kg cmH2O cmH2O torr
1 M 3.0 3 wk Bilateral CDH,
Di George
syndrome
Post correction
CDH
50 7 7.24 58 116 91 20.9
2 F 3.0 5 wk TGA Post switch
operation
21 7 7.37 46 39 135 10.4
3 F 8.5 18 m Agranulocytosis Post lung biopsy 28 5 7.27 43 36 61 27.8
4 F 55.8 12 y Post renal TX CMV-pneumonia 40 15 7.07 92 81 203 14.7
5 F 5.4 4 m Omenn syndrome Idiopathic 38 10 7.22 63 96 53 39.6
6 F 34.0 10 y ANLL, post
bone marrow TX
Pneumonia 34 20 7.26 57 39 60 43.3
7 F 4.2 6 m Down, AVSD,
duodenal
web, tracheo-
bronchomalacia
Chronic lung
disease
18 10 7.38 49 26 215 6.5
8 M 7.6 8 m Down,
ex-premature,
BPD
Varicella
pneumonia
30 14 7.33 64 58 83 24.1
9 F 13 23 m Mitochondrial
enzymopathy
Idiopathic 30 16 7.26 68 41 81 27.1
wk, weeks; m, months; y, years; CDH, congenital diaphragmatic hernia; TGA, transposition of great arteries; TX, transplantation; CMV-
pneumonia, cytomegalovirus; ANLL, acute non-lymphatic leukaemia; AVSD, atrio-ventriculum septum defect; BPD, bronchopulmonary
dysplasia; MVI, modified ventilatory index, respiratory rate  PaCO2 (torr)  PIP (cmH2O)/1000; OI, oxygenation index FiO2  100  CDP
(cmH2O)/PaO2 (torr).
94 E.L.I.M. Duval et al.in OI on t2 (pZ 0.028) and t3 (pZ 0.046). OI after 72 h
decreased to 6.8 (4.8e9.5). Patients 4 and 6, who died from
respiratory failure, are represented separately, showing an
increasing OI (Figure 2). Figure 3 shows the PaCO2 (torr) oftime
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Figure 1 Boxplot of OI values of all patients prior to and
during the first 72 h on HFOV. TCMV represents the PaCO2 on
CMV prior to HFOV, T1, T2, T3 and T4 after stabilisation, 24, 48
and 72 h on HFOV, respectively. *p < 0.05.all patients. Statistical significance was reached after 48
and 72 h with a decrease from 58 mmHg (48e66) pre-HFOV
to 50 mmHg (pZ 0.046) and 41 mmHg (pZ 0.042) respec-
tively. Figure 4 shows the PaO2/FiO2 ratio: at baseline the
median was 113 (82e206); after 24 and 48 h of HFOV the
PaO2/FIO2 ratio had increased significantly to 214
(pZ 0.012) and 210 (pZ 0.018) respectively.
One patient developed a new airleak during HFOV (iso-
lated pneumomediastinum). Three needed additional
circulatory support during transition (one fluid resuscita-
tion, two also inotrope support), there were no other signs0
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Figure 2 OI values of non-responders prior to and during the
first 72 h on HFOV. TCMV represents the PaCO2 on CMV prior to
HFOV, T1, T2, T3 and T4 after stabilisation, 24, 48 and 72 h on
HFOV, respectively.
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Figure 3 Boxplot of PaCO2 values (torr) of all patients prior
to and during the first 72 h on HFOV. TCMV represents the
PaCO2 on CMV prior to HFOV, T1, T2, T3 and T4 after stabili-
sation, 24, 48 and 72 h on HFOV respectively. *p < 0.05.
HFOV in severe lung haemorrhage 95of cardiac compromise in the remaining patients. Prone
position was used also during HFOV to improve oxygenation.
No other additional therapies were used.
Two of the patients died due to respiratory failure. The
first patient was a 10-year-old girl with acute leukaemia,time
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Figure 4 Boxplot of PaO2/FiO2 ratio of all responders prior to
and during the first 72 h on HFOV. TCMV represents the PaCO2
on CMV prior to HFOV, T1, T2, T3 and T4 after stabilisation, 24,
48 and 72 h on HFOV respectively. *p < 0.05.whose post bone marrow transplantation course was
complicated with sepsis and HPO, uncontrollable with PEEP
levels up to 20 cmH2O. HFOV was initiated 2 h after
admission to our unit, but the bleeding could not be
stopped with a maximum CDP of 45 cmH2O, and she died
within a few hours. The second patient was a 13-year-old
girl who acquired CMV-pneumonia after renal trans-
plantation. After 4 days of ventilation she had a profuse
bleeding, successfully treated with HFOV. A second episode
of HPO on the third day appeared untreatable even with
a CDP of 45 cmH2O, an inspiratory time up to 50% and prone
position. Both of these two non-responders showed severe
disseminated intravascular coagulation (DIC). Two other
patients died because of therapy withdrawal due to non-
pulmonary causes; they were responding well on the
oscillator, with a decrease of the OI from 28 to 7 for patient
3 and from 40 to 7 for patient 5, respectively.
All but one survivor were weaned directly from HFOV to
CPAP and extubated 1 day later. Two patients needed
oxygen after 28 days, one with pre-existent broncho-
pulmonary dysplasia. All were discharged home without
supplemental oxygen.
Discussion
Our findings suggest that HFOV could be a safe rescue
therapy in treating children with massive pulmonary hae-
morrhage. Although a rare event in childhood, pulmonary
haemorrhage might be life threatening, requiring imme-
diate intervention.1,3,4,10,16 In 1922, Browne reported six
cases of what he called ‘‘acute haemorrhagic pneumonia’’
characterised by lung haemorrhage.11 Cole et al. in 1973
suggested that the term haemorrhagic pulmonary oedema
might more accurately describe this condition. They
demonstrated that the effluent was almost always hae-
morrhagic oedema rather than whole blood and suggested
that increased pulmonary capillary pressures due to acute
left ventricular failure after asphyxia, acidosis and brady-
cardia were the main factors in the pathogenesis.2 Nowa-
days, HPO is considered to be hemorrhagic oedema
resulting from shear stress of pulmonary capillaries asso-
ciated with lung overdistension, inadequate protective
surface tension and fragility of the pulmonary capillary
wall.12
HPO in childhood results from a wide aetiologic spec-
trum: cardiovascular malformations, infectious processes,
mycotoxins, milk protein allergy and immune vasculitis.13
It has recently been revised to include those conditions
with and without pulmonary capillaritis.14 It may occur
in the setting of vasculitis syndromes (Wegener’s gran-
ulomatosis, systemic lupus erythematosus and Good-
pasture’s syndrome). In this setting, a therapeutic role has
been suggested for high-dose steroids. Coagulopathies and
tracheobronchial trauma may lead to true haemorrhage.
This is different in the neonatal period, where the
underlying cause is most likely an increase in the pulmonary
blood flow through a patent ductus arteriosus, which could
be potentiated by other disorders like asphyxia, infection
and coagulopathy.15e17 Since exogenous surfactant was
introduced, frequency of HPO in premature respiratory
distress syndrome has increased.17e19 It is postulated that
after surfactant exposure, pulmonary vascular resistance
Table 2 Overview of the literature.
Baden et al.28 De Jongh
et al.29
Pappas
et al.30
Cheng et al.31 Ko et al.1 Chavez
et al.10
Haselto
et al.32
Al Kharfy17 Chalak et al.26
No. of cases 2 2 6 1 18 1 1 17 1
Age (range) Infants Adults 0.9e6 m 60 y Neonates (gest.
age 25e41 wk)
1 m 6 yr Neonates
(gest. age
24e29 wk)
Neonate
(gest. age
24 wk)
Cause of HPO Post arterial
switch operation
During
ECMO
Idiopathic
(Stachybotrys
atra?)
Perioperatively
for aortic
dissection repair
PDA (nZ 11),
surfactant (nZ 7)
MAS (nZ 2)
asphyxia (nZ 1)
Idiopathic
(cow milk?)
Post BM x PDA (nZ 10),
coagulopathy
(nZ 3),
unknown
(nZ 5)
Persistent
pulmonary
hypertension,
PDA
Prior mode
of CMV
CMV, PIP 50 cmH2O
PEEP 10e15 cmH2O
CMV, PC-mode Separate
CMV with
double
lumen tube
CMV, PC-mode CMV, P mode CMV, Paw >
12 cmH2O,
FiO2 0.8 þ
pH <7.28
Was already
on HFV with
CDP of
9 cmH2O
and amplitude
of 28
Duration on CMV
(range)
< 1 h 1e10 days <1 h 2 he6 d 1 d 7 h 42e91 h 3 d
Mode of HFV HFOV HFJV HFJV þ CMV
(nZ 2)
HFJV for the
affected lung
HFOV HFOV Flow interrupter HFV
HFOV (nZ 4)
OI on CMV (range) 10e49 Survivors: 10e20 Survivors: 26  12
Non-survivors: 8e11 Non-survivors:
59  27
Initial settings
on HFV
CDP 24e30 cmH2O HFJV (PIPZ
PIP CMV)
þ CMV
(PEEP 5 cmH2O)
Driving pressure
30 PSI, fr
150 bpm, PEEP
24 cmH2O
CDPZ Paw on
CMV þ 2e3 cmH2O
CDP of 2 cmH2O
HFOV (CDPZ
Paw on CMV)
Days on HFV
(range)
2e8 0.8e5.1 <1 Survivors:0.5e8.1 3 8 Survivors 1e5 12 d
Non-survivors
0.4e1.3
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HFOV in severe lung haemorrhage 97decreases and that the increase in left to right shunting and
lung compliance results in an acute rise in lung capillary
pressure, leading to pulmonary haemorrhage.4,20
Data on incidence in children is lacking. In neonates
occurrence of HPO has been estimated at 0.7e 3.8 events
per 1000 living births.16e19 In the 1990s, the incidence in
children was increased in several Midwestern U.S. cities.
Although no obvious cause was established, the toxigenic
fungus Stachybotrys atra was found in almost all of the case
homes studied. These spores carry several classes of toxins,
which could lead to formation of fragile capillaries,
subsequently at risk for stress haemorrhage.15,20,21
The poor prognosis of HPO was finally challenged when
Cole and Entress,22 and in the late 1970s Trompeter et al.23
and Castile and Kleinber,24 described survival after treat-
ment with mechanical ventilation. Currently, approxi-
mately 50% of infants who suffer from HPO survive.4
The first step in the treatment of HPO is to assess and
ensure an adequate airway and ventilation: life threatening
to these patients is asphyxia, rather than massive blood
loss. The source of bleeding is usually difficult to detect.
Selective intubation may be attempted but is often difficult
in children, especially when the right upper lobe is
involved.25,26 Emergency bronchoscopy may be performed
to localise the focus which may be controlled with pressure
or topical therapy. If the bleeding persists, arteriography
with selective embolisation or surgical resection of the
bleeding focus may be required.27
The use of high-frequency ventilation (HFV) in HPO has
not been extensively described in the literature. Table 2
shows an overview of all the reports in English on the use of
HFV in children and adults with HPO.1,10,26,28e32 There was
a total of 49 patients, 5 treated with high-frequency jet
ventilation, 25 with HFOV, 17 with high-frequency flow
interrupter and in two patients the HFV mode is not spec-
ified. Thirty-five patients survived (71.4%) and 12 died. The
cause of death was uncontrollable haemorrhage in two and
severe airleak syndrome in three patients. It was unspeci-
fied in seven patients; they all died within 24 h after initi-
ation of HFOV. Similar to our report, OI was significantly
decreased in the survivors. In our patients the ‘‘open-lung
strategy’’ was employed during HFOV, with high CDP,
designed primarily to rapidly recruit and maintain lung
volume in diffuse alveolar disease. However, during lung
haemorrhage the high CDP tamponades the transudation of
haemorrhagic oedema and cells from engorged capillaries,
and decreases blood flow from ruptured vessels by
increasing intrathoracic pressure and reducing pulmonary
blood flow.33
In addition, increases in intrathoracic pressure decrease
intrathoracic blood volume and venous return and indi-
rectly help to reduce the transmural intrathoracic vascular
pressure. Respiratory mortality rate was two out of nine
patients (22%), comparable to overall mortality of HPO on
HFV. Similar to previous trials, an increasing OI was specific
for imminent death.5e7,9,17 Our two non-responders repre-
sented true haemorrhages with severe DIC. Since the
underlying conditions causing DIC and pulmonary haemor-
rhage could not be successfully treated, mechanical
ventilation did not influence their outcome. When they
were transferred to HFOV, the more powerful SensorMedics
3100B, enabling the use of higher CDP and bias flow, was
98 E.L.I.M. Duval et al.not yet available. The 3100A with a maximal CDP of
45 cmH2O proved to be insufficient for both children with
weights of 34 kg and 56 kg respectively. Our data include
only nine patients, a sample too small to make any
conclusive result. Further research should focus on trying to
determine which patient would benefit from rescuing
therapy with HFOV and/or which subgroup will need addi-
tional therapy.
To conclude, HFOV can be effective in massive pulmo-
nary haemorrhage with rapid improvement in oxygenation
and ultimately life-saving effects in this often fatal condi-
tion. The use of high distending pressures aims at tampo-
nading transudation of oedema and cells from capillaries,
and decreasing blood flow from ruptured pre-capillary
arterioles by reducing pulmonary blood flow and increasing
intrathoracic pressure.
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